Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain
Gastroenterol Hepatol. 2020 Feb;43(2):79-86.
doi: 10.1016/j.gastrohep.2019.08.012.
Epub 2019 Nov 29.
[Article in
English,
Spanish]
Authors
Ignasi Puig
1
, Erwin Sanabria
2
, Faust Feu
3
, Ignacio Couto
4
, Marta Blanco
4
, Pedro Alonso
4
, Javier P Gisbert
5
, Adrian G McNicholl
5
, Agustín Seoane
6
, Felipe Bory
6
, Francisco Polo
7
, Víctor Orivé
7
, Julio Ponce
8
, Fernando Borda
9
, Antonio Hervás
10
, Ángeles Pérez-Aisa
11
, Robin Rivera
11
, Enrique Quintero
12
, David Nicolás-Pérez
13
, Luis Bujanda
14
, Luis Rodrigo
15
, Xavier Calvet
16
; Spanish Gastroenterological Association Gastroduodenal Diseases Study Group
Affiliations
- 1 Digestive Diseases Department, Althaia Xarxa Assistencial Universitària de Manresa, Barcelona, Spain; Universitat Internacional de Catalunya, Barcelona, Spain.
- 2 Department of Gastroenterology, Institut de Malalties Digestives i Metabòliques, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- 3 Department of Gastroenterology, Institut de Malalties Digestives i Metabòliques, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- 4 Digestive Diseases Department, Complexo Hospitalario Universitario A Coruña, La Coruña, Spain.
- 5 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
- 6 Digestive Diseases Department, Hospital del Mar, Barcelona, Spain.
- 7 Digestive Diseases Department, Hospital Basurto, Bilbao, Spain.
- 8 Digestive Diseases Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
- 9 Digestive Diseases Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
- 10 Digestive Diseases Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
- 11 Digestive Diseases Department, Agencia Sanitaria Costa del Sol, Marbella, Spain.
- 12 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Digestive Diseases Department, Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, Spain; Gastroenterology Department, Hospital Universitario Donostia/Biodonostia Institute, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
- 13 Digestive Diseases Department, Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, Spain.
- 14 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Gastroenterology Department, Hospital Universitario Donostia/Biodonostia Institute, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
- 15 Digestive Diseases Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
- 16 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Digestive Diseases Department, Corporación Sanitaria Parc Taulí, Sabadell, Spain; Departament de Medicina, Facultat de Medicina, Universitat Autònoma de Barcelona, Spain. Electronic address: XCalvet@tauli.cat.
Abstract
Introduction:
Cure of Helicobacter pylori infection in patients with gastric lymphoma of mucosa-associated lymphoid tissue (MALT) leads to long-term clinical remission in the initial stages. As it is a rare disease, its management in clinical practice remains largely unknown and heterogeneity of care remains a concern. The aim was to audit the management and evolution of a large series of low-grade gastric MALT lymphomas from thirteen Spanish hospitals.
Materials and methods:
Multicentre retrospective study including data on the diagnosis and follow-up of patients with gastric low-grade MALT lymphoma from January 1998 to December 2013. Clinical, biological and pathological data were analyzed and survival curves were drawn.
Results:
One-hundred and ninety-eight patients were included. Helicobacter pylori was present in 132 (69%) patients and 103 (82%) in tumors confined to the stomach (stage EI) and was eradicated in 92% of patients. Chemotherapy was given in 90 (45%) patients and 43 (33%) with stage EI. Marked heterogeneity in the use of diagnostic methods and chemotherapy was observed. Five-year overall survival was 86% (89% in EI). Survival was similar in EI patients receiving aggressive treatment and in those receiving only antibiotics (p=0.577).
Discussion:
Gastric MALT lymphoma has an excellent prognosis. We observed, however, a marked heterogeneity in the use of diagnostic methods or chemotherapy in early-stage patients.
Keywords:
Disease management; Estudios de seguimiento; Follow-up studies; Linfoma; Lymphoma; Mortalidad; Mortality; Neoplasias malignas; Stomach neoplasms; Tratamiento de la enfermedad.
Copyright © 2019 Elsevier España, S.L.U. All rights reserved.
Publication types
-
Comparative Study
-
Multicenter Study
MeSH terms
-
Aged
-
Clinical Audit
-
Female
-
Helicobacter pylori / isolation & purification
-
Humans
-
Lymphoma, B-Cell, Marginal Zone / diagnosis*
-
Lymphoma, B-Cell, Marginal Zone / microbiology
-
Lymphoma, B-Cell, Marginal Zone / pathology
-
Lymphoma, B-Cell, Marginal Zone / therapy*
-
Male
-
Middle Aged
-
Neoplasm Grading
-
Practice Patterns, Physicians'
-
Retrospective Studies
-
Spain
-
Stomach Neoplasms / diagnosis*
-
Stomach Neoplasms / microbiology
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / therapy*